Elevated Heart Rate in Combination with Elevated Blood Pressure Predicts Lower Cardiovascular Mortality in Acute Decompensated Heart Failure.


Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
28 Mar 2020
Historique:
pubmed: 17 3 2020
medline: 9 4 2020
entrez: 17 3 2020
Statut: ppublish

Résumé

Despite its clinical relevance, a subclass of acute decompensated heart failure (ADHF) with elevated blood pressure, known as hypertensive ADHF (HT-ADHF), has been less intensively evaluated. This study aimed to characterize the prognostic nature and pathophysiology of HT-ADHF. A total of 509 consecutive patients with first-time ADHF hospitalization were subjects of the study. Participants were divided into two groups: an HT-ADHF group (systolic blood pressure, SBP > 140 mmHg at presentation) and a non-HT-ADHF group (SBP ≤ 140 mmHg). Median follow-up duration measured 253 days. Unadjusted Kaplan-Meier analysis demonstrated both a lower cardiovascular mortality rate in the HT-ADHF group and similar incidences of heart failure rehospitalization in both groups. Adjusted Cox hazard analysis showed an association of elevated SBP at presentation with significantly lower cardiovascular mortality, though no such association was observed with heart failure rehospitalization. Moreover, elevated heart rate in combination with elevated SBP at presentation predicted a significantly lower risk of cardiovascular mortality (Hazard Ratio: 0.32, 95% CI: 0.14-0.77, P = 0.01). Also, significantly lower cardiovascular mortality was observed in this subtype, compared with other types of ADHF.

Identifiants

pubmed: 32173710
doi: 10.1536/ihj.19-521
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

308-315

Auteurs

Masaru Hiki (M)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.

Hiroshi Iwata (H)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.

Kiyoshi Takasu (K)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.

Shuko Nojiri (S)

Medical Technology Innovation Center, Juntendo University.

Go Ishikawa (G)

Department of Cardiovascular Medicine, Juntendo University Nerima Hospital.

Yuichi Chikata (Y)

Department of Cardiovascular Medicine, Juntendo University Nerima Hospital.

Peter C Mattson (P)

Warren Alpert Medical School, Providence.

Takatoshi Kasai (T)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.

Tetsuro Miyazaki (T)

Department of Cardiovascular Medicine, Juntendo University Urayasu Hospital.

Kenji Inoue (K)

Department of Cardiovascular Medicine, Juntendo University Nerima Hospital.

Yasumasa Fujiwara (Y)

Department of Cardiovascular Medicine, Juntendo University Nerima Hospital.

Masataka Sumiyoshi (M)

Department of Cardiovascular Medicine, Juntendo University Nerima Hospital.

Koichiro Kinugawa (K)

Second Department of Internal Medicine, University of Toyama.

Hiroyuki Daida (H)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH